RecruitingPhase 1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

United States8 participantsStarted 2025-08-22

Plain-language summary

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. NAFLD Activity Score (NAS) ≥ 4 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH Clinical Research Network (CRN) fibrosis score of F0 OR
✓. NAS ≥ 3 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH CRN fibrosis score of F1 OR
✓. NAS ≥ 2 (with at least 1 point in subcomponent of ballooning or inflammation) and a NASH CRN fibrosis score of F2-3

What they're measuring

Change in fasting hepatic lipogenesis after 6 weeks of treatment

Timeframe: Baseline to Week 6

Change in peak lipogenesis after 6 weeks of treatment.

Timeframe: Baseline to Week 6

Trial details

NCT IDNCT06947304

SponsorCorcept Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05

Contact for this trial

Elizabeth Parks, PhD

(573) 882-5864 parksej@missouri.edu

View on ClinicalTrials.gov More Nonalcoholic Steatohepatitis (NASH) trials